Contact
searchSearch
HMP Global

Commentary

Commentary
What Not To Do in an Office-Based Lab
03/08/2024

Moiz Shah, MD1; John Blebea MD, MBA2

1National Registry, Outpatient Endovascular and Interventional Society, Chicago, Illinois; 2Department of Surgery, College of Medicine, Central Michigan University, Saginaw, Michigan

Moiz Shah, MD1; John Blebea MD, MBA21...
Careful selection of which cases not to take is an effective way of avoiding complications in an OBL. Determining what cases to avoid is largely dependent on 4 major variables: the physician, the patient, the procedure, and the OBL itself.
Careful selection of which cases not to take is an effective way of avoiding complications in an OBL. Determining what cases to avoid is largely dependent on 4 major variables: the physician, the patient, the procedure, and the OBL itself.
Careful selection of which cases...
03/08/2024
Vascular Disease Management
OEIS logo
Commentary
OEIS Response to Recent Media Articles Regarding Outpatient Vascular Care
08/02/2023

OEIS Executive Committee

OEIS Executive Committee
One-sided stories do not tell the whole story of the CLI/CLTI epidemic and omit the vast, overwhelming majority of patients who successfully undergo limb salvage/preservation. OEIS believes the better story is one that educates the public...
One-sided stories do not tell the whole story of the CLI/CLTI epidemic and omit the vast, overwhelming majority of patients who successfully undergo limb salvage/preservation. OEIS believes the better story is one that educates the public...
One-sided stories do not tell...
08/02/2023
Vascular Disease Management
Commentary
Platelet Mapping Highlights Our Burgeoning Understanding of Sex Dimorphism in Vascular Disease—and All That We Have Yet to Learn
11/16/2022
Can we delineate objective differences in responsiveness to antiplatelet medications between the sexes to explain why women with PAD have fewer risk factors yet higher rates of nonhealing and amputation?
Can we delineate objective differences in responsiveness to antiplatelet medications between the sexes to explain why women with PAD have fewer risk factors yet higher rates of nonhealing and amputation?
Can we delineate objective...
11/16/2022
Vascular Disease Management
Commentary
Is There a Role for Edetate Disodium Chelation in PAD and Specifically CLTI?
10/12/2022
In this commentary, the authors review edetate disodium chelation therapy and its use in patients with PAD and CLTI.
In this commentary, the authors review edetate disodium chelation therapy and its use in patients with PAD and CLTI.
In this commentary, the authors...
10/12/2022
Vascular Disease Management
Commentary
Catheterization, Myocardial Infarction, and the COVID-19 Pandemic: The Devil Is in the Details
12/17/2021
Drs. Aijaz and Garcia comment on this issue's Original Research article by Al-Abdouh et al.
Drs. Aijaz and Garcia comment on this issue's Original Research article by Al-Abdouh et al.
Drs. Aijaz and Garcia comment on...
12/17/2021
Vascular Disease Management
Editorial/Commentary
Proper Shielding Technique in Protecting Against Scatter Radiation
06/11/2021
Radiation shielding can provide effective protection from scatter radiation during vascular angiographic procedures.
Radiation shielding can provide effective protection from scatter radiation during vascular angiographic procedures.
Radiation shielding can provide...
06/11/2021
Vascular Disease Management
Commentary
The First Well-Documented Report of Carotid Endarterectomy in a Patient With COVID-19 Related Stroke
05/11/2020
The COVID-19 pandemic has caused sudden and severe illness with high mortality and threatens to overwhelm healthcare systems.
The COVID-19 pandemic has caused sudden and severe illness with high mortality and threatens to overwhelm healthcare systems.
The COVID-19 pandemic has caused...
05/11/2020
Vascular Disease Management
Commentary Regarding Katsanos et al's Meta-Analysis: The Lessons Learned Should Impose Prudence and Caution
Commentary
Commentary Regarding Katsanos et al's Meta-Analysis: The Lessons Learned Should Impose Prudence and Caution
01/14/2020
Francesco Liistro, MD, comments on the meta-analysis presented by Katsanos et al.
Francesco Liistro, MD, comments on the meta-analysis presented by Katsanos et al.
Francesco Liistro, MD, comments...
01/14/2020
Vascular Disease Management
Commentary
Technology Must Meet Efficacy in Treating ALI
11/04/2019
Paul Michael, MD, comments on a single-center, observational experience of patients treated for acute limb ischemia by Estes and colleagues, and congratulates the group for wanting to constantly improve their state of thrombolysis therapy.
Paul Michael, MD, comments on a single-center, observational experience of patients treated for acute limb ischemia by Estes and colleagues, and congratulates the group for wanting to constantly improve their state of thrombolysis therapy.
Paul Michael, MD, comments on a...
11/04/2019
Vascular Disease Management
Commentary
Vascular Closure Devices for Antegrade Punctures: The Evidence is Mounting
09/13/2018
In this editorial commentary, Sahil A. Parikh, MD, discusses the accumulating research behind vascular closure devices for antegrade punctures, including the VASCADE Vascular Closure System for closure of arterial and venous access sites.
In this editorial commentary, Sahil A. Parikh, MD, discusses the accumulating research behind vascular closure devices for antegrade punctures, including the VASCADE Vascular Closure System for closure of arterial and venous access sites.
In this editorial commentary,...
09/13/2018
Vascular Disease Management

Stay in the Know

Vascular Disease Management Newsletter

News

First Aid guidelines
AHA/American Red Cross: Updated First Aid Guidelines Enhance Care for Opioid Overdose, Bleeding, Other Emergencies
11/14/2024
These are the first major comprehensive updates to the first aid guidelines since 2010 and address shifts in how the public manages common and critical first aid emergencies.
These are the first major comprehensive updates to the first aid guidelines since 2010 and address shifts in how the public manages common and critical first aid emergencies.
These are the first major...
11/14/2024
Cath Lab Digest
Late-Breaking Trials
Final Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/06/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final round of Late-Breaking Clinical Trials presented at...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final round of Late-Breaking Clinical Trials presented at...
The VIVA Foundation, a...
11/06/2024
Vascular Disease Management
Late-Breaking Trials
Third Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/05/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the third of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the third of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a...
11/05/2024
Vascular Disease Management
Late-Breaking Trials
Second Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/04/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a...
11/04/2024
Vascular Disease Management
Late-Breaking Trials
First Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/04/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a...
11/04/2024
Vascular Disease Management
Image-Guided Therapy
Philips Enrolls First Patient in U.S. Clinical Trial for Innovative Integrated Single-Device to Treat Peripheral Artery Disease
11/04/2024
With a unique world-first ability to perform laser atherectomy and laser-based intravascular lithotripsy using a single device, Philips takes a major step forward in the treatment of peripheral artery disease (PAD) Cardiovascular...
With a unique world-first ability to perform laser atherectomy and laser-based intravascular lithotripsy using a single device, Philips takes a major step forward in the treatment of peripheral artery disease (PAD) Cardiovascular...
With a unique world-first...
11/04/2024
Vascular Disease Management
Pulmonary Embolism
Akura Medical Secures FDA Approval for US Pivotal Trial in Pulmonary Embolism
11/04/2024
QUADRA-PE study will evaluate the safety and effectiveness of the Katana™ Thrombectomy System LOS GATOS, Calif., Nov. 4, 2024 /PRNewswire/ -- Akura Medical, a Shifamed portfolio company focused on reshaping the...
QUADRA-PE study will evaluate the safety and effectiveness of the Katana™ Thrombectomy System LOS GATOS, Calif., Nov. 4, 2024 /PRNewswire/ -- Akura Medical, a Shifamed portfolio company focused on reshaping the...
QUADRA-PE study will evaluate...
11/04/2024
Vascular Disease Management
Peripheral Arterial Disease
FDA Grants R3 Vascular IDE Approval for ELITE-BTK Pivotal Trial of its MAGNITUDE® Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease
11/04/2024
MOUNTAIN VIEW, Calif. – November 4, 2024 – R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce...
MOUNTAIN VIEW, Calif. – November 4, 2024 – R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce...
MOUNTAIN VIEW, Calif. – November...
11/04/2024
Vascular Disease Management
Patient Awareness
Baby Boomers Beware: More Americans Than Ever Before Now at Higher Risk for Common Blood Vessel Diseases
10/31/2024
New survey reveals nearly one in three Americans at highest risk for blood vessel diseases and life-threatening complications report low awareness Society for Vascular Surgery launches the Highway to Health campaign to help people maintain...
New survey reveals nearly one in three Americans at highest risk for blood vessel diseases and life-threatening complications report low awareness Society for Vascular Surgery launches the Highway to Health campaign to help people maintain...
New survey reveals nearly one in...
10/31/2024
Vascular Disease Management
DCB
SIRONA Trial @TCT – First Head-to-Head Comparison of Sirolimus Versus Paclitaxel DCBs in the Treatment of PAD: Sirolimus-Coated Balloons Yield Similar Results to Paclitaxel-Coated Balloons in the Femoropopliteal Artery
10/30/2024
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...
Data from the prospective,...
10/30/2024
Cath Lab Digest

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use